[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT05706558":3,"trial-entities:NCT05706558":93,"trial-summary:NCT05706558":98},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":6,"overall_status":7,"completion_date":8,"status_verified_date":9,"last_update_date":10,"start_date":11,"sponsor_name":12,"lead_sponsor_class":13,"has_dmc":14,"brief_summary":15,"detailed_description":14,"conditions":16,"keywords":19,"study_type":20,"primary_purpose":14,"phases":21,"enrollment_info":22,"interventions":25,"primary_outcomes":33,"secondary_outcomes":38,"sex":48,"minimum_age":49,"maximum_age":14,"healthy_volunteers":50,"eligibility_criteria":51,"std_ages":62,"locations":65,"central_contacts":79,"overall_officials":86,"references":89,"see_also_links":90},"NCT05706558","16-1631","Retrospective Review of Esophageal Cancer at MSKCC","RECRUITING","2027-02","2026-09","2026-09-09","2016-12-13","Memorial Sloan Kettering Cancer Center","OTHER",null,"Residual tumor at the proximal or distal margin after esophagectomy is a known prognostic factor for poor survival outcomes in patients with esophageal cancer; however, the significance of the circumferential resection margin (CRM) remains controversial. In this study, the investigators sought to evaluate the prognostic significance of the CRM in patients with esophageal cancer undergoing resection.",[17,18],"Esophageal Cancer","Esophagus Cancer",[17,18,12,5],"OBSERVATIONAL",[],{"count":23,"type":24},4000,"ESTIMATED",[26],{"type":27,"name":28,"description":28,"armGroupLabels":29},"PROCEDURE","Esophagectomy",[30,31,32],"Circumferential resection margin (CRM)","Circumferential resection margin (CRM)+","Circumferential resection margin (CRM)-close",[34],{"measure":35,"description":36,"timeFrame":37},". Preoperative variables associated with overall survival and progression-free survival (measured from date of surgery)","Preoperative variables associated with overall survival and progression-free survival (measured from date of surgery) and the association between patient characteristics, neoadjuvant therapy, and postoperative morbidity.","Up to 2 years",[39,42,44,46],{"measure":40,"description":41,"timeFrame":37},"Overall survival and progression-free survival (measured from date of surgery)","Postoperative outcomes stratified by the type of esophageal cancer surgery performed.",{"measure":43,"timeFrame":37},"Postoperative outcomes stratified by the time between neoadjuvant therapy and surgery (i.e., delayed or immediate).",{"measure":45,"timeFrame":37},"Survival outcomes stratified by treatment modality (i.e., definitive chemoradiation therapy or trimodality treatment).",{"measure":47,"timeFrame":37},"Survival outcomes stratified by use of adjuvant therapy (i.e., adjuvant therapy or no adjuvant therapy).","ALL","18 Years",false,{"inclusion":52,"exclusion":55,"raw_text":61},[53,54],"Histologically confirmed esophageal adenocarcinoma (EAC) or esophageal squamous cell carcinoma (ESCC) undergoing esophagectomy","Pathologic staged T3 tumors (pT3)",[56,57,58,59,60],"Pathologic staged T0-2 (pT0-2) or T4 tumors (pT4)","Patients with histologic types other than EAC or ESCC, dysplasia or carcinoma in situ without tumor invasion,","Patients undergoing salvage esophagectomy","Evidence of distant metastatic disease","Patients with a positive proximal or distal margin","Inclusion Criteria:\n\n* Histologically confirmed esophageal adenocarcinoma (EAC) or esophageal squamous cell carcinoma (ESCC) undergoing esophagectomy\n* Pathologic staged T3 tumors (pT3)\n\nExclusion Criteria:\n\n* Pathologic staged T0-2 (pT0-2) or T4 tumors (pT4)\n* Patients with histologic types other than EAC or ESCC, dysplasia or carcinoma in situ without tumor invasion,\n* Patients undergoing salvage esophagectomy\n* Evidence of distant metastatic disease\n* Patients with a positive proximal or distal margin",[63,64],"ADULT","OLDER_ADULT",[66],{"facility":67,"status":7,"city":68,"state":68,"zip":69,"country":70,"contacts":71,"geoPoint":76},"Memorial Sloan Kettering Cancer Center (All Protocol Activities)","New York","10065","United States",[72],{"name":73,"role":74,"phone":75},"Daniela Molena, MD","CONTACT","212-639-3870",{"lat":77,"lon":78},40.71427,-74.00597,[80,82],{"name":73,"role":74,"phone":75,"email":81},"molenad@mskcc.org",{"name":83,"role":74,"phone":84,"email":85},"James Isbell, MD","212-639-6247","isbellj@mskcc.org",[87],{"name":73,"affiliation":12,"role":88},"PRINCIPAL_INVESTIGATOR",[],[91],{"label":12,"url":92},"http:\u002F\u002Fwww.mskcc.org",{"nct_id":4,"conditions":94,"biomarkers":97},[95,96],"Esophageal Adenocarcinoma","Esophageal Squamous Cell Carcinoma",[],{"nct_id":4,"found":99,"summary":100,"prompt_version":109},true,{"design":101,"status":102,"heading":6,"summary":103,"follow_up":104,"word_count":105,"commitments":106,"compensation":107,"drugs_mentioned":108},"This is an observational study, meaning researchers are reviewing existing patient data. It aims to include 4000 participants.","completed","This study is looking back at information from patients who have had surgery (esophagectomy) for esophageal cancer. Researchers want to understand if the amount of tumor left at the edges of the removed tissue, specifically the circumferential resection margin (CRM), affects how long patients live without their cancer returning (progression-free survival) and overall survival. You might be eligible if you are 18 or older, have been diagnosed with esophageal adenocarcinoma (EAC) or esophageal squamous cell carcinoma (ESCC), and had a specific type of tumor (pT3) removed during your esophagectomy. The study aims to include about 4000 participants. The current recruitment status is unclear.","The study will look at survival outcomes for up to 2 years after surgery.",103,"Not specified in the trial record.","Not stated in the trial record.",[28],"v2"]